Peptides

A synthetic peptide for use as a blocking control in assays to test for specificity of TRPM5 antibody, catalog no. 70R-5146

A synthetic peptide for use as a blocking control in assays to test for specificity of RALA antibody, catalog no. 70R-9415

A synthetic peptide for use as a blocking control in assays to test for specificity of SSX1 antibody, catalog no. 70R-9559

Custom research peptide; min purity 95%.

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM20C antibody, catalog no. 70R-6352

A synthetic peptide for use as a blocking control in assays to test for specificity of MARS antibody, catalog no. 70R-7943

A synthetic peptide for use as a blocking control in assays to test for specificity of ABCD2 antibody, catalog no. 70R-8567

A synthetic peptide for use as a blocking control in assays to test for specificity of CSTB antibody, catalog no. 70R-2262

A synthetic peptide for use as a blocking control in assays to test for specificity of TMCC3 antibody, catalog no. 70R-6900

A synthetic peptide for use as a blocking control in assays to test for specificity of HSPE1 antibody, catalog no. 70R-4219

A synthetic peptide for use as a blocking control in assays to test for specificity of EDIL3 antibody, catalog no. 70R-9143

A synthetic peptide for use as a blocking control in assays to test for specificity of SPTAN1 antibody, catalog no. 70R-2207

A synthetic peptide for use as a blocking control in assays to test for specificity of FAM120C antibody, catalog no. 70R-10170

A synthetic peptide for use as a blocking control in assays to test for specificity of UPF3B antibody, catalog no. 70R-1348

A synthetic peptide for use as a blocking control in assays to test for specificity of KCNJ9 antibody, catalog no. 70R-5156

A synthetic peptide for use as a blocking control in assays to test for specificity of SCG3 antibody, catalog no. 70R-9777

A synthetic peptide for use as a blocking control in assays to test for specificity of UBQLN3 antibody, catalog no. 70R-2645

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF708 antibody, catalog no. 70R-8963

A synthetic peptide for use as a blocking control in assays to test for specificity of SLC16A1 antibody, catalog no. 70R-1756

A synthetic peptide for use as a blocking control in assays to test for specificity of IFIT5 antibody, catalog no. 70R-5819

A synthetic peptide for use as a blocking control in assays to test for specificity of TNKS antibody, catalog no. 70R-2849

A synthetic peptide for use as a blocking control in assays to test for specificity of ZNF668 antibody, catalog no. 70R-7997

A synthetic peptide for use as a blocking control in assays to test for specificity of PUS7 antibody, catalog no. 70R-1241

A synthetic peptide for use as a blocking control in assays to test for specificity of AGXT2L1 antibody, catalog no. 70R-2601

A synthetic peptide for use as a blocking control in assays to test for specificity of ASL antibody, catalog no. 70R-1176

Beta-Sheet Breaker Peptide iAß5 is a peptide that interacts with amyloid beta proteins to disrupt the formation of beta sheets. It has been shown to inhibit the aggregation of amyloid beta proteins into oligomers and fibrils, and disrupts the self-assembly of amyloid beta protein into various conformations. Beta-Sheet Breaker Peptide iAß5 is a ligand for both receptor and activator binding sites on amyloid beta proteins, inhibiting the interaction of these sites. This inhibits the activation of downstream signalling pathways associated with Alzheimer's disease.

A synthetic peptide for use as a blocking control in assays to test for specificity of HABP2 antibody, catalog no. 70R-6071

A synthetic peptide for use as a blocking control in assays to test for specificity of RPS6 antibody, catalog no. 70R-10315

A synthetic peptide for use as a blocking control in assays to test for specificity of FCRL1 antibody, catalog no. 70R-1853

A synthetic peptide for use as a blocking control in assays to test for specificity of NRP1 antibody, catalog no. 70R-9671

A synthetic peptide for use as a blocking control in assays to test for specificity of FBLN1 antibody, catalog no. 70R-5356

Insulin is a hormone that regulates the metabolism of carbohydrates and fats. It is produced by beta cells in the pancreas and prevents hyperglycemia. Insulin binds to insulin-specific receptors on the cell membrane, resulting in increased glucose uptake by muscle and fat cells. Monoclonal Mouse Anti-Human Insulin is an antibody that binds to human insulin and blocks its action, thereby lowering blood sugar levels. This antibody was immunised with human insulin and purified from mouse spleen cells. The antibody has been shown to block glycogen synthesis and fatty acid synthesis in vitro. Monoclonal Mouse Anti-Human Insulin also has a high binding affinity for erythrocytes and penetrates these cells easily. When injected into humans, this antibody binds to the erythrocytes in the blood stream and prevents their passage through capillary walls into tissues such as muscle or fat cells, thereby preventing glycolysis (the conversion of glucose into energy) in those tissues

A synthetic peptide for use as a blocking control in assays to test for specificity of VISA antibody, catalog no. 70R-6463

A synthetic peptide for use as a blocking control in assays to test for specificity of DPH2 antibody, catalog no. 70R-3392

Stresscopin-Related Peptide (Human) is a protein that belongs to the class of peptides. The peptide is an activator of receptor for glucocorticoids, and it also can bind with other receptors. Stresscopin-Related Peptide (Human) has been shown to interact with ion channels and ligands, such as antibodies, in the human body. This product is purified to ≥98% and available in a research grade form. It is not intended for use in humans or animals.

MOG(35-55) human corresponds to amino acids 35 to 55 of the human myelin oligodendrocyte glycoprotein (MOG). It can be used in multiple sclerosis research to induce experimental autoimmune encephalomyelitis (EAE) in mouse and rat models.

A synthetic peptide for use as a blocking control in assays to test for specificity of PSMD1 antibody, catalog no. 70R-5638

A synthetic peptide for use as a blocking control in assays to test for specificity of ZGPAT antibody, catalog no. 70R-4430

A synthetic peptide for use as a blocking control in assays to test for specificity of C9orf68 antibody, catalog no. 70R-4309

A synthetic peptide for use as a blocking control in assays to test for specificity of ACADS antibody, catalog no. 70R-2485

AMY1A is a tryptic peptide derived from the alpha-amylase 1 from the salivary gland of the fruit fly, Drosophila melanogaster. Alpha-amylase 1 is a member of the amylase family and has been shown to be biologically active in vitro. AMY1A is used as a calibrator for mass spectrometry and proteomics applications. It is also used in conjunction with other peptides to identify proteins in proteomic experiments.

A synthetic peptide for use as a blocking control in assays to test for specificity of CDCA5 antibody, catalog no. 70R-2883

A synthetic peptide for use as a blocking control in assays to test for specificity of TXNDC13 antibody, catalog no. 70R-7432

A synthetic peptide for use as a blocking control in assays to test for specificity of SLCO1C1 antibody, catalog no. 70R-6553

A synthetic peptide for use as a blocking control in assays to test for specificity of ZDHHC14 antibody, catalog no. 70R-7047

A synthetic peptide for use as a blocking control in assays to test for specificity of RHOT1 antibody, catalog no. 70R-5953

A synthetic peptide for use as a blocking control in assays to test for specificity of JPH1 antibody, catalog no. 70R-1819

A synthetic peptide for use as a blocking control in assays to test for specificity of SMPD1 antibody, catalog no. 70R-7120

A synthetic peptide for use as a blocking control in assays to test for specificity of C10orf83 antibody, catalog no. 70R-3297

A synthetic peptide for use as a blocking control in assays to test for specificity of GNAI3 antibody, catalog no. 70R-9627

Adropin is a peptide that binds to the activator domain of phospholipase A2 (PLA2) and inhibits the enzyme. It has been shown to be an inhibitor of PLA2 in human, mouse, and rat cells. Adropin can also inhibit ion channels and cell signaling pathways by binding to cell surface receptors. This research tool may be used for studying protein interactions and pharmacology.

Suc-Ala-Ala-pNA is a synthetic peptide that has been shown to inhibit the activity of enzymes in the metabolic pathway of cholesterol biosynthesis. It also inhibits the activity of phospholipase A2 and cyclooxygenase, which are involved in arachidonic acid metabolism. Suc-Ala-Ala-pNA is a hydrophobic molecule that can be used as an inhibitor for enzymes such as esterases, aminopeptidases, amidases, carboxypeptidases, and proteases. Suc-Ala-Ala-pNA has been shown to have antiatherosclerotic properties because it inhibits the production of lipid peroxides.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Extraordinary strength of the streptavidin-biotin interaction allows for efficient capturing of even highly dilute targets; however, it makes recovery of proteins from affinity resins challenging. Conventional methods to elute biotinylated proteins from immobilized avidin include the following: (i) denaturation of streptavidin by boiling the resin in a denaturing buffer that may include high concentrations of chaotropic salts, (ii) trypsin digestion of proteins while they are bound to the resin, or (iii) elution of proteins with excess free biotin. These protocols can co-elute contaminant proteins by releasing nonspecifically bound proteins and/or naturally biotinylated proteins concurrently with labeled proteins. In addition, some of these methods can cause elution of high levels of resin-based peptides along with the proteins of interest, resulting in further sample contamination.
Disulfide Biotin Azide probe eliminates a major limitation of the streptavidin-biotin affinity purification. This reagent contains a biotin moiety linked to an azide moiety through a spacer arm containing a cleavable disulfide linker. Captured biomolecules can be efficiently released under mild conditions (50 mM dithiothreitol, 10 mM 2-mercaptoethanol or 1% sodium borohydride) and the small molecular fragment (188.25 Da) left on the labeled protein following cleavage. These features make the cleavable probe especially attractive for use in biomolecular labeling and proteomic studies.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Please enquire for more information about Fluorescein-6-carbonyl-Leu-Glu(OMe)-His-DL-Asp(OMe)-fluoromethylketone including the price, delivery time and more detailed product information at the technical inquiry form on this page

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Myelin oligodendrocyte glycoprotein (MOG) is a myelin protein found in the central nervous system. MOG is a ligand for CD200, which is an inhibitory receptor expressed by astrocytes. It has been shown that MOG can induce the proliferation and differentiation of primary cultures of rat astrocytes in vitro. MOG induces the production of reactive oxygen species in mitochondria and increases the expression of acid-binding protein, which are both important factors in the demyelination process. MOG has also been implicated as a potential factor in the development of multiple sclerosis. Further research into this protein may lead to new treatments or cures for disorders such as encephalomyelitis, nervous system diseases, or even cancer.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

CJC-1295 is a synthetic peptide, which is an analogue of growth hormone-releasing hormone (GHRH). It is synthesized through recombinant DNA technology, which allows for precise control over its sequence and length. This particular peptide is designed to bind to GHRH receptors in the pituitary gland. By activating these receptors, CJC-1295 stimulates the release of growth hormone (GH) into the bloodstream.The primary function of CJC-1295 is to influence the endocrine system, particularly enhancing the release of endogenous growth hormone. It achieves this by increasing the amplitude and frequency of GH pulses without affecting the natural negative feedback mechanisms that regulate GH production. This mode of action distinguishes CJC-1295 from other growth hormone therapies, as it promotes a more physiological pattern of hormone secretion.CJC-1295 is used in various scientific contexts, primarily in research focusing on growth hormone deficiencies, muscle wasting conditions, and certain metabolic disorders. Its ability to increase GH release also makes it a subject of interest in studies related to aging, tissue repair, and regeneration. The longer half-life of CJC-1295 compared to natural GHRH peptides further enhances its applications in research, allowing for more sustained and controlled experimentation.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

H-His-Arg-OH is a synthetic peptide that has been shown to have cytotoxic effects on mammalian cells. The H-His-Arg-OH peptide can be used for the treatment of heart disease and autoimmune diseases, such as rheumatoid arthritis. This peptide has been found to be resistant to congestive heart failure, which is caused by a number of factors, including hypertension and valvular stenosis. It has also been shown to have an immunoglobulin G1 (IgG1) genotype.

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity

Catalogue peptide; min. 95% purity